About the Author
Jim Ruble, PharmD, JD, is executive associate dean and professor at the University of Utah College of Pharmacy in Salt Lake City.
Publication
Article
Pharmacy Times
Author(s):
The law has support from patients, health care providers, pharmacists, and the largest health insurance provider in the state.
Prior authorizations (PAs) are pervasive in the delivery of US health care. They are a tool used by government and private health insurers to control costs and to ensure resources are being optimally utilized. Although developed for good fiscal management practices, PAs have also been prone to abuse and can lead to delays in necessary treatment. They have shifted an administrative burden onto medical practices and pharmacies to the degree that many physicians’ practices employ staff whose sole responsibility is to process PAs.1
Image credit: Maksim Shchur | stock.adobe.com
In May 2025, the Alaska Legislature passed SB 133, which requires insurers to notify patients of PA decisions within 72 hours of the request submission. This law applies to PA requests for medical services and prescription drugs. Within this 72-hour range, the insurer can request additional information from the health care provider, which provides a limited extension of time for decision notification. The law includes a path for expedited requests, which must have a decision within 24 hours.2
Jim Ruble, PharmD, JD, is executive associate dean and professor at the University of Utah College of Pharmacy in Salt Lake City.
The new legislation becomes effective January 1, 2026. The law is described as having support from patients, health care providers, pharmacies, and the largest health insurance provider in the state. In a statement, legislative sponsor Sen Jesse Bjorkman stated, “[T]his bill makes the process quicker, clearer, and fairer for everyone.”2
For several years, the American Medical Association has advocated for changes in medical service PAs, and a Centers for Medicare & Medicaid Services (CMS) final rule in 2024 implemented similar times for PA decisions.3 This policy is referred to as the Interoperability and Patient Access Final Rule. The CMS rule also required insurers to improve application programming interfaces (APIs). In simple terms, APIs are interfaces that increase communication between computer systems and enhance automation of decisions. The CMS interoperability rule streamlined administrative burden in medical practices, but the rule specifically excluded PA decisions regarding prescription medications.3 The American Pharmacists Association advocated for the CMS rule to cover medications.
Presently, there is a robust public discourse on drug pricing mechanisms and levels of transparency in decision-making processes. Although not under the same magnification as pharmacy benefit managers, PAs and API computer systems are poised to be an emerging strategy for advocacy for patients and improvements in pharmacy operations and finances.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
2 Commerce Drive
Cranbury, NJ 08512